All In Biotech

Drug Trial Radar · NCT07750665

FXS6837 for the Treatment for IgAN Patients(Longterm Study)

A Study to Evaluate the Long-term Efficacy and Safety of FXS6837 in IgAN Patients

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Nov 13, 2029

Study completion Jan 4, 2030

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.

Conditions

  • Primary IgAN

Interventions

  • FXS6837 CapsuleDrug

    FXS6837 capsule orally taken according to protocol for 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: through study completion, an average of 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.